Medication persistence among people with multiple sclerosis in Slovenia treated with dimethyl fumarate

References

• World Health Organization & Multiple Sclerosis International Federation. 2008). Atlas: multiple sclerosis resources in the world 2008. World Health Organization. https://apps.who.int/iris/handle/10665/43968. (Accessed 10.9. 2022).
   Google Scholar
• Rovaris M, Confavreux C, Furlan R, et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol. 2006;5(4):343–354. doi: 10.1016/S1474-4422(06)70410-0.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi: 10.1016/S1474-4422(17)30470-2.
   PubMed Web of Science ®Google Scholar
• Thomas RH, Wakefield RA. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis. Am J Health Syst Pharm. 2015; Jan 172(1):25–38. doi: 10.2146/ajhp140023.
   PubMed Web of Science ®Google Scholar
• Rot U, Brecl-Jakob G, Šega-Jazbec S, et al. Disease-modifying therapy for multiple sclerosis in Slovenia: analysis of 20 years of treatment. Rad Hrvatske akademije znanosti i umjetnosti. 2022;58–59(58–59):28–34. https://hrcak.srce.hr/280797 (Accessed 10.6. 2022) doi: 10.21857/mjrl3ug069.
   Google Scholar
• Ockenfels HM, Schultewolter T, Ockenfels G, et al. The antipsoriatic agent dimethylfumarate immunomodulates T-cell cytokine secretion and inhibits cytokines of the psoriatic cytokine network. Br J Dermatol. 1998;139(3):390–395. doi: 10.1046/j.1365-2133.1998.02400.x.
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–1107. doi: 10.1056/NEJMoa1114287.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–1097. doi: 10.1056/NEJMoa1206328.
   PubMed Web of Science ®Google Scholar
• van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 2013;368(17):1658–1659. doi: 10.1056/NEJMc1215357.
   PubMed Web of Science ®Google Scholar
• Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med. 2013;368(17):1657–1658. doi: 10.1056/NEJMc1211805.
   PubMed Web of Science ®Google Scholar
• Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705. doi: 10.1111/j.1365-2125.2012.04167.x.
   PubMed Web of Science ®Google Scholar
• Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):449–457.
   PubMed Web of Science ®Google Scholar
• Vollmer WM, Xu M, Feldstein A, et al. Comparison of pharmacy-based measures of medication adherence. BMC Health Serv Res. 2012;12(1):155. doi: 10.1186/1472-6963-12-155.
   PubMed Web of Science ®Google Scholar
• Moride Y, Ducruet T, Rochon S, et al. Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Rheumatology. 2003;42 Suppl 3(90003):iii17–iii22. doi: 10.1093/rheumatology/keg494.
   PubMedGoogle Scholar
• Larsen J, Andersen M, Kragstrup J, et al. High persistence of statin use in a Danish population: compliance study 1993-1998. Br J Clin Pharmacol. 2002;53(4):375–378. doi: 10.1046/j.1365-2125.2002.01563.x.
   PubMed Web of Science ®Google Scholar
• Reardon G, Schwartz GF, Mozaffari E. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol. 2003;13(4_suppl):S44–S52. doi: 10.1177/112067210301304s05.
   PubMedGoogle Scholar
• Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol. 2004;137(1 Suppl):S13–S16. doi: 10.1016/j.ajo.2003.10.034.
   PubMedGoogle Scholar
• Nicholas JA, Edwards NC, Edwards RA, et al. Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. BMC Neurol. 2020;20(1):281. doi: 10.1186/s12883-020-01830-0.
   PubMed Web of Science ®Google Scholar
• Thomas NP, Curkendall S, Farr AM, et al. The impact of persistence with therapy on inpatient admissions and emergency room visits in the US among patients with multiple sclerosis. J Med Econ. 2016;19(5):497–505. doi: 10.3111/13696998.2015.1134546.
   PubMed Web of Science ®Google Scholar
• Reynolds MW, Stephen R, Seaman C, et al. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs. J Med Econ. 2010;13(1):90–98. doi: 10.3111/13696990903579501.
   PubMedGoogle Scholar
• Polman C, Reingold S, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302. doi: 10.1002/ana.22366.
   PubMed Web of Science ®Google Scholar
• Dima AL, Dediu D. Computation of adherence to medication and visualization of medication histories in R with AdhererR: towards transparent and reproducible use of electronic healthcare data. PLOS One. 2017;12(4):e0174426. doi: 10.1371/journal.pone.0174426.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444.
   PubMed Web of Science ®Google Scholar
• Lahdenperä S, Soilu-Hänninen M, Kuusisto HM, et al. Medication adherence/persistence among patients with active multiple sclerosis in Finland. Acta Neurol Scand. 2020;142(6):605–612. doi: 10.1111/ane.13301.
   PubMed Web of Science ®Google Scholar
• Hersh CM, Love TE, Bandyopadhyay A, et al. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. Mult Scler J Exp Transl Clin. 2017;3(3):2055217317715485. doi: 10.1177/2055217317715485.
   Google Scholar
• Johnson KM, Zhou H, Lin F, et al. Real-world adherence and persistence to oral disease-modifying therapies in multiple sclerosis patients over 1 year. J Manag Care Spec Pharm. 2017;23(8):844–852. doi: 10.18553/jmcp.2017.23.8.844.
   PubMedGoogle Scholar
• Eriksson I, Cars T, Piehl F, et al. Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study. Eur J Clin Pharmacol. 2018;74(2):219–226. doi: 10.1007/s00228-017-2366-4.
   PubMed Web of Science ®Google Scholar
• Nazareth T, Friedman HS, Navaratnam P, et al. Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review. BMC Neurol. 2016;16(1):187. doi: 10.1186/s12883-016-0698-9.
   PubMedGoogle Scholar
• Wray S, Then Bergh F, Wundes A, et al. Efficacy and safety outcomes with diroximel fumarate after switching from prior therapies or continuing on DRF: results from the phase 3 EVOLVE-MS-1 study. Adv Ther. 2022;39(4):1810–1831. doi: 10.1007/s12325-022-02068-7.
   PubMed Web of Science ®Google Scholar
• Grytten N, Aarseth JH, Espeset K, et al. Stoppers and non-starters of disease-modifying treatment in multiple sclerosis. Acta Neurol Scand. 2013;127(2):133–140. doi: 10.1111/j.1600-0404.2012.01708.x.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Danni M, Taffi R, et al. Persistence to oral disease-modifying therapies in multiple sclerosis patients. J Neurol. 2017;264(11):2325–2329. doi: 10.1007/s00415-017-8595-8.
   PubMed Web of Science ®Google Scholar
• Dima AL, Hernandez G, Cunillera O, et al. Asthma inhaler adherence determinants in adults: systematic review of observational data. Eur Respir J. 2015;45(4):994–1018. doi: 10.1183/09031936.00172114.
   PubMed Web of Science ®Google Scholar
• Higuera L, Carlin, CS, Anderson S. Adherence to disease-modifying therapies for multiple sclerosis. J Manag Care Spec Pharm. 2016;22(12):13.
   Web of Science ®Google Scholar